GlassScriptPhysician profile
Todd R Coven
NPI 1215943121
$1,768.82
in general payments reported to CMS, 2019-2025
24 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $72.47 · 2021: $241 · 2022: $221 · 2023: $509 · 2024: $152 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,133.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $529.85 | 2019-2025 | Rinvoq, Skyrizi |
| Incyte Corporation | $260.13 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $110.73 | 2021-2025 | Libtayo |
| Sun Pharmaceutical Industries INC. | $100.86 | 2020-2025 | |
| Janssen Biotech, INC. | $98.22 | 2023-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.96 | 2022-2023 | Spevigo |
| Almirall LLC | $91.72 | 2021-2025 | Klisyri |
| Novartis Pharmaceuticals Corporation | $69.32 | 2021-2025 | |
| Organogenesis INC. | $59.98 | 2022-2023 | Puraply |
| Neurent Medical Limited | $45.82 | 2024 | Neuromark Radiofrequency Console, Neuromark Device |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $40.04 | 2019-2021 | |
| Genentech USA, INC. | $39.43 | 2019-2021 | |
| Lilly USA, LLC | $36.59 | 2022-2024 | Olumiant |
| Leo Pharma INC. | $26.51 | 2019 | |
| Kerecis Limited | $22.96 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $21.30 | 2021 | |
| Verrica Pharmaceuticals INC. | $20.81 | 2025 | Ycanth |
| Paratek Pharmaceuticals, INC. | $20.62 | 2023 | Nuzyra |
| Genentech, INC. | $17.79 | 2023 | Erivedge |
| Vyne Pharmaceuticals INC. | $17.31 | 2020 | |
| Mayne Pharma Commercial LLC | $13.98 | 2019 | |
| Misonix INC | $12.60 | 2021 | |
| Pierre Fabre Pharmaceuticals, INC. | $11.17 | 2019 | |
| Organon LLC | $8.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Todd Coven listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.